Can Immunotherapy Combined With Antiangiogenic Therapy Be a Breakthrough for Driver-Negative Non-small-Cell Lung Cancer Patients With Performance Status of 3-4 in the First-Line Setting? | Am J Ther;2020 Dec 28. | MEDLINE

Conteúdo principal 1 Busca 2 Rodapé 3

+A A -A Alto contraste

Secretaria de Estado da Saúde - BVS

Rede de Informação e Conhecimento

Localizar descritor de assunto Busca Avançada

Can Immunotherapy Combined With Antiangiogenic Therapy Be a Breakthrough for Driver-Negative Non-small-Cell Lung Cancer Patients With Performance Status of 3-4 in the First-Line Setting?

Wang, Yanning; Zhou, Yujie; Miao, Liyun.

Afiliação

Wang Y; Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital,Nanjing, China Department of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University.

Am J Ther ; 2020 Dec 28.

Article em En | MEDLINE | ID: mdl-33395049

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article